Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of resistance to HER2 target therapy.

Journal of the National Cancer Institute. Monographs - 1 Jan 2011

Tortora Giampaolo

Abstract excerpt

In the past years, several agents targeting signaling proteins critical for breast cancer growth and dissemination entered clinical evaluation. They include drugs directed against the HER/ErbB family of receptor tyrosine kinases, especially HER2; several downstream signal transducers; and proteins involved in tumor angiogenesis and dissemination. Unfortunately, resistance to targeted agents is a quite common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Drug Resistance, Neoplasm

Share to Receptor, ErbB-2

Share to Signal Transduction

Share to Trastuzumab

Source

Identifiers

PMID: 22043051
DOI: 10.1093/jncimonographs/lgr026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of resistance to HER2 target therapy.PMID 22043051Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

Mechanisms of lapatinib resistance in HER2-driven breast cancer.Semantic proximity Read ↗

New agents for endocrine resistance in breast cancer.Semantic proximity Read ↗

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceSemantic proximity Read ↗

Molecular aspects of breast cancer resistance to drugs (Review).Semantic proximity Read ↗

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].Semantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.Semantic proximity Read ↗

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.